Financial Performance - HBC recorded total operating revenues of NOK 68.4 million in Q2 2025, down from NOK 80.4 million in Q2 2024, with net operating revenues at NOK 67.8 million compared to NOK 72.2 million year-over-year [1] - EBITDA for Q2 2025 was negative NOK 5.4 million, worsening from negative NOK 2.0 million in Q2 2024, while the first six months showed a loss of NOK 25.3 million compared to NOK 18.2 million in the same period last year [2] - Operational EBITDA for Q2 2025 was positive NOK 1.3 million, an improvement from negative NOK 2.5 million in the same quarter last year, while the first six months recorded an Operational EBITDA of negative NOK 7.0 million [2] Liquidity Position - Cash and cash equivalents decreased by NOK 3.9 million during Q2 2025, totaling NOK 68.0 million at the end of the quarter, which is an increase from NOK 25.3 million a year earlier [3] - Total liquidity, including available credit lines, reached NOK 76.5 million as of June 30, 2025 [3] Product and Market Developments - Human Nutrition B2B Sales surged 180% year-over-year to NOK 9.3 million, driven by strong demand in Europe, China, and Southeast Asia [8] - OmeGo® and ProGo® led product launches, supported by scientific validation, with ProGo® winning the "Panpan Cup" Food Maker Award in China [8] - Brilliant Salmon Oil is now available in over 25 countries, with new listings in Italy, Ireland, Taiwan, UAE, and Ecuador, and further distribution agreements in Japan, Czech Republic, and Ukraine are in progress [8] Scientific and Research Advancements - HBC emphasizes scientific evidence, leading to academic partnerships and unique health benefits, including improved iron metabolism and immune health benefits from ProGo® and OmeGo® [7] - CalGo® has shown benefits for bone and joint health, supporting healthy aging and active lifestyles, with ongoing studies and publications planned for ProGo® cognitive health in Alzheimer's [8]